Suppr超能文献

鉴定巨大芽孢杆菌种内 CYP102A1 的多种天然变体。

Characterization of diverse natural variants of CYP102A1 found within a species of Bacillus megaterium.

机构信息

School of Biological Sciences and Technology, Chonnam National University, Gwangju 500-757, Republic of Korea.

出版信息

AMB Express. 2011 Mar 28;1(1):1. doi: 10.1186/2191-0855-1-1.

Abstract

An extreme diversity of substrates and catalytic reactions of cytochrome P450 (P450) enzymes is considered to be the consequence of evolutionary adaptation driven by different metabolic or environmental demands. Here we report the presence of numerous natural variants of P450 BM3 (CYP102A1) within a species of Bacillus megaterium. Extensive amino acid substitutions (up to 5% of the total 1049 amino acid residues) were identified from the variants. Phylogenetic analyses suggest that this P450 gene evolve more rapidly than the rRNA gene locus. It was found that key catalytic residues in the substrate channel and active site are retained. Although there were no apparent variations in hydroxylation activity towards myristic acid (C14) and palmitic acid (C16), the hydroxylation rates of lauric acid (C12) by the variants varied in the range of >25-fold. Interestingly, catalytic activities of the variants are promiscuous towards non-natural substrates including human P450 substrates. It can be suggested that CYP102A1 variants can acquire new catalytic activities through site-specific mutations distal to the active site.

摘要

细胞色素 P450(CYP)酶的底物和催化反应具有极强的多样性,被认为是不同代谢或环境需求驱动的进化适应的结果。本文报道了巨大芽孢杆菌(Bacillus megaterium)种内存在大量的 CYP102A1(P450 BM3)天然变体。从这些变体中鉴定出大量的氨基酸取代(占总 1049 个氨基酸残基的 5%)。系统进化分析表明,该 P450 基因的进化速度比 rRNA 基因座快。研究发现,底物通道和活性部位的关键催化残基得以保留。尽管变体对十四烷酸(C14)和棕榈酸(C16)的羟基化活性没有明显差异,但变体对月桂酸(C12)的羟基化速率差异高达 25 倍以上。有趣的是,变体对包括人 P450 底物在内的非天然底物具有混杂的催化活性。可以推测,CYP102A1 变体可以通过远离活性部位的特定位置突变获得新的催化活性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/da0a/3159907/77e06b7a7742/2191-0855-1-1-1.jpg

相似文献

3
Engineering cytochrome P450 BM3 of Bacillus megaterium for terminal oxidation of palmitic acid.
J Biotechnol. 2014 Aug 20;184:17-26. doi: 10.1016/j.jbiotec.2014.05.002. Epub 2014 May 14.
4
Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Drug Metab Dispos. 2010 May;38(5):732-9. doi: 10.1124/dmd.109.030759. Epub 2010 Jan 25.
5
Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Drug Metab Dispos. 2011 Jan;39(1):140-50. doi: 10.1124/dmd.110.036392. Epub 2010 Oct 20.
8
The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities.
Trends Biotechnol. 2007 Jul;25(7):289-98. doi: 10.1016/j.tibtech.2007.05.003. Epub 2007 May 29.
9
Filling a hole in cytochrome P450 BM3 improves substrate binding and catalytic efficiency.
J Mol Biol. 2007 Oct 26;373(3):633-51. doi: 10.1016/j.jmb.2007.08.015. Epub 2007 Aug 21.
10
Construction of a thermostable cytochrome P450 chimera derived from self-sufficient mesophilic parents.
Appl Microbiol Biotechnol. 2007 Jul;75(5):1055-61. doi: 10.1007/s00253-007-0922-z. Epub 2007 Apr 28.

引用本文的文献

1
Choose Your Own Adventure: A Comprehensive Database of Reactions Catalyzed by Cytochrome P450 BM3 Variants.
ACS Catal. 2024 Mar 29;14(8):5560-5592. doi: 10.1021/acscatal.4c00086. eCollection 2024 Apr 19.
2
The Versatile Biocatalyst of Cytochrome P450 CYP102A1: Structure, Function, and Engineering.
Molecules. 2023 Jul 12;28(14):5353. doi: 10.3390/molecules28145353.
3
Oleic acid based experimental evolution of Bacillus megaterium yielding an enhanced P450 BM3 variant.
BMC Biotechnol. 2022 Jul 13;22(1):20. doi: 10.1186/s12896-022-00750-w.
4
A Novel Statin Compound from Monacolin J Produced Using CYP102A1-Catalyzed Regioselective C-Hydroxylation.
Pharmaceuticals (Basel). 2021 Sep 26;14(10):981. doi: 10.3390/ph14100981.

本文引用的文献

1
Generation of human chiral metabolites of simvastatin and lovastatin by bacterial CYP102A1 mutants.
Drug Metab Dispos. 2011 Jan;39(1):140-50. doi: 10.1124/dmd.110.036392. Epub 2010 Oct 20.
3
Engineering bacterial cytochrome P450 (P450) BM3 into a prototype with human P450 enzyme activity using indigo formation.
Drug Metab Dispos. 2010 May;38(5):732-9. doi: 10.1124/dmd.109.030759. Epub 2010 Jan 25.
4
A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds.
Chemistry. 2009 Nov 2;15(43):11723-9. doi: 10.1002/chem.200900643.
5
Interpretation and considerations on the safety evaluation of human drug metabolites.
Chem Res Toxicol. 2009 Jul;22(7):1217-20. doi: 10.1021/tx900124j.
6
A highly active single-mutation variant of P450BM3 (CYP102A1).
Chembiochem. 2009 Jul 6;10(10):1654-6. doi: 10.1002/cbic.200900279.
7
Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3.
Drug Metab Dispos. 2009 May;37(5):932-6. doi: 10.1124/dmd.108.026484. Epub 2009 Feb 23.
9
Phylogeny in aid of the present and novel microbial lineages: diversity in Bacillus.
PLoS One. 2009;4(2):e4438. doi: 10.1371/journal.pone.0004438. Epub 2009 Feb 12.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验